tbuckley/cabot-search huggingface dataset:
582P Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study
Authors: D. Basile, M. Polano, P. Di Nardo, C. Gallois, S.K. Garattini, E. ongaro, L. Foltran, D. Girimonte, L. Gerratana, C. Cortese, D.S. Marco, A. Cordua, M. Ventura, N. Pella, A. Zaanan, G. Aprile, V. Canzonieri, J. Taieb, F. Puglisi
Journal: Annals of Oncology (2024)
613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) &amp; BRAF-altered solid tumors
Authors: P. Cassier, J.M. Mehnert, R. Kim, B. Chmielowski, M. Millward, C.A. Perez, M. Gonzalez Cao, V. Gambardella, M. Mckean, M.S. Brose, Y. Xing, G.V. Long, A. Kelly, G. Lee, P. Severson, R. Williams, C. Gaudy Marqueste
Journal: Annals of Oncology (2024)
588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Authors: V. Martelli, J. Vidal Barrull, C. Fernandez Rodriguez, R.D.A. Toledo, J. Gibert, P. García Alfonso, D. Paez, V. Alonso-Orduna, M.A. Gomez España, C. Santos Vivas, G. Duran Ogaya, M.E. Elez Fernandez, R. Garcia-Carbonero, R. Ferreiro Monteagudo, J.L. Manzano Mozo, B. Bellosillo Paricio, J. Tabernero, R. Salazar Soler, E. Aranda Aguilar, C. Montagut Viladot
Journal: Annals of Oncology (2024)
604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors
Authors: A.G. Sacher, M. Villalona-Calero, B.H. O’Neil, J. Rodon, T. Doi, S. Postel-Vinay, F. Ghiringhelli, N. Yamamoto, S. Wahlroos, L. Villaruz, A. El-Helali, Y. Fujiwara, A. Addeo, C-C. Lin, E. Fontana, C-H. Chuang, C. Liu, T. Eggert, N. Penel, H. Prenen
Journal: Annals of Oncology (2024)
617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study
Authors: M. Simonelli, D. Lorusso, K. Homicsko, F. Seguy, M. Kinder, Q. Liu, E. Croft, S. Kitano
Journal: Annals of Oncology (2024)
587P Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Authors: F. Schietroma, G. Caira, A. Spring, G. Trovato, G. Valente, A. Ceccarelli, L. Chiofalo, S. Perazzo, A. Cosmai, L. Di Francesco, C. Pozzo, M. Basso, T. pasciuto, L. Giacò, C. Nero, A. Minucci, L. Salvatore, G. Scambia, G. Tortora, M.A. Calegari
Journal: Annals of Oncology (2024)
618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors
Authors: T.A. Yap, F. Yan, S. Sadeghi, T.T. Lin, F. Liu, L. Malky, M. Golmakani, A. Moreau, H. Neumann, L. Zhou, D. Juric, M.R. Sharma
Journal: Annals of Oncology (2024)
639P Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Authors: S. Cousin, L. Belcaid, L-J. Palmieri, A. Bayle, S. Taleb, M. Aldea, M. Alamé, L. Blouin, I. Soubeyran, A. Hollebecque, Y. Loriot, B. Besse, L. lacroix, E. Rouleau, J-C. Soria, F. Barlesi, F. André, C.P. Massard, A. Italiano
Journal: Annals of Oncology (2024)
1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials
Authors: E. Grist, P. Dutey-Magni, L. Mendes, M.A. Parry, A. Sachdeva, J. Proudfoot, A.A. Hamid, C.L. Amos, W. Cross, S. Gillessen, D.M. Berney, M.R. Sydes, M.K. Parmar, F. Feng, N. Clarke, E. Davicioni, C. Sweeney, N.D. James, L.C. Brown, G. Attard
Journal: Annals of Oncology (2024)
1515P Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study
Authors: R. Takada, K. Ikezawa, H. Takahashi, T. Satoh, T. Taira, S. Kobayashi, Y. Negoro, S. Kobayashi, N. Kato, S. Nara, W. Izumo, H. Morita, S. Orihara, M. Taguri, H. Imaoka, H. Yanagimoto, C. Morizane, M. Ueno, J. Furuse, H. Nagano
Journal: Annals of Oncology (2024)
1583P Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Authors: L.F. Leite, M.V.M.G. da Silva, L. Diniz, J.S.A. de Menezes, E.M. Souza Filho, M. Silveira Vilbert, A. Spreafico, E.F. Saldanha
Journal: Annals of Oncology (2024)
1570P Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Authors: Y. Ji, F. Zhou, H. Qu, J. Wang, M. Liu, W. Liang, G. Dai, Q. Wu, J. Luo, X. Tan, G. Hu, H. Wang, Q. Meng, Y. Ren, W. liu, W. He, Z. Qin, H. Tang, H. Liu, Z. Yu
Journal: Annals of Oncology (2024)
1574P Medical oncology residents mentors (MORM): A target for resiliency interventions
Authors: D. Paez, A. Lecumberri, A. Soria Rivas, L.A. Leon Mateos, H. García-Martinez, U. Anido Herranz, C. Castanon Lopez, M.E. Elez Fernandez, I. Fernandez-Rañada Shaw, L.C. Iglesias Docampo
Journal: Annals of Oncology (2024)
1594P Cancer mortality in young population and estimated radon areas in Spain
Authors: M. Ferriol-Galmés, J.C. Laguna Montes, E. Auclin, M. Garcia De Herreros, F.J. Muñoz i Carrillo, T. Gorría Puga, M.B. Bernabeu Aracil, M. Jiménez, A. Bedmar, M. García Pardo de Santayana, D. Martinez, A.F. Navarro Mendivil, N. Reguart Aransay, L. Alcolea, A. Clua, G. Castellano, C. Teixido, R. López Castro, P. Barlet-Ros, L. Mezquita
Journal: Annals of Oncology (2024)
1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Authors: L.G. Horvath, H-M. Lin, I.D. Davis, A. Martin, T. Scheinberg, P. Meikle, A. Joshua, M. Mcjannett, V. Subhash, S. Yip, S. North, R.S. McDermott, K.N. Chi, M.R. Stockler, C. Sweeney
Journal: Annals of Oncology (2024)
1600P Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Authors: U.N. Vaishampayan, D. Kilari, T.B. Dorff, J. Taylor, J.T. Brown, A.O. Sokolova, Z. Reichert, P. Palmbos, I. Tsung, M. Caram, S. Yentz, J. Alumkal, B. Nazha
Journal: Annals of Oncology (2024)
1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: D. Rathkopf, M.R. Patel, A.D. Choudhury, D. Rasco, N.J. Lakhani, J. Hawley, S. Srinivas, A. Aparicio, V. Narayan, K. Runcie, H. Emamekhoo, Z. Reichert, H. Nguyen, A. Wells, R. Kandimalla, S. Suryawanshi, J. Wu, V. Arora, M. Pourdehnad, A.J. Armstrong
Journal: Annals of Oncology (2024)
1513P Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
Authors: O. Pitiyarachchi, F.P. Lin, A. Spooner, G. Sharbeen, H.P. Barker, K. Thornton, E. Collignon, M.L. Ballinger, D.M. Thomas, A. Magenau, S. Porazinski, A. Raina, K.M. Sjoquist, L.A. Chantrill, V. Gebski, A. Sowmya, P. Timpson, M. Pajic, D. Goldstein, P.A. Phillips
Journal: Annals of Oncology (2024)
1577P Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Authors: M. Garcia De Herreros, M.B. Bernabeu Aracil, M. Ferriol-Galmés, F.J. Muñoz i Carrillo, S. Medina Valdivieso, H. Arasanz, S. Vazquez Estevez, S. Catort Tort, L.A. Leon Mateos, R. Alvarez Cabellos, P. Cruz Castellanos, G. Rubio Romero, L. Aguilar Corominas, L. Alcolea Contreras, A. Arcocha, M. Jiménez, J.C. Laguna Montes, C. Teixido, R. López Castro, L. Mezquita
Journal: Annals of Oncology (2024)
1582P Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Authors: L. Incorvaia, T.D. Bazan Russo, A. Perez, C. Brando, P. Ferraro, A. Simone, M. Bono, L. Castellana, L. Insalaco, S. Contino, A. Gottardo, V. Gristina, A. Galvano, L.R. Corsini, D. Fanale, G. Badalamenti, A. Russo, V. Bazan
Journal: Annals of Oncology (2024)
1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Authors: S.B. van Waalwijk van Doorn-Khosrovani, A.H. Huisman, H.J.L. Timmer, K. Verkerk, F. Verbeek, L. Fagereng, A. Helland, B. Ryll, K. Tasken, K. Jalkanen, J. Oliveira, U.N. Lassen, J-Y. Blay, H. Gelderblom, A. Reyners, F.A. Eskens, E.F. Smit, E.E. Voest, H. Bloemendal
Journal: Annals of Oncology (2024)
1606P Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Authors: A. Holmes, C. Thomas, A.R. Fajardo, M. Sun, S. Huicochea Castellanos, D.M. Nanus, C.N. Sternberg, A.M. Molina, S. Yuan, V. Avlonitis, A. Patel, P. Gregos, J. Osborne, N.H. Bander, S.T. Tagawa
Journal: Annals of Oncology (2024)
1595MO Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial
Authors: C. Pobel, C. Bargain, J. Scoazec, E. Rouleau, G. Roubaud, P. Ronchin, S. Supiot, A. Hasbini, M. Silva, A. Flechon, B. Laguerre, S. Abadie Lacourtoisie, C. El Kouri, L. Mourey, T. Maurina, E. Martin, H. Ribault, S. Foulon, K. Fizazi, Y. Loriot
Journal: Annals of Oncology (2024)
1590P Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Authors: S. Priou, M. Barclay, A. Cohen, M. Verdoux, R. Flicoteaux, A. Laurent, G. Chatellier, C. Tournigand, G. Lyratzopoulos, E. Kempf, G. Lamé
Journal: Annals of Oncology (2024)
1585P Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Authors: G.M. Iannantuono, M. Filetti, E. Giudice, S. Sganga, E.B.A. Chandran, E. Xue, P. Lombardi, R. Rosenfeld, E. Rapisarda, L. Ferri, G. De Rubeis, D. Lorusso, C. Floudas, J.L. Gulley, A.B. Apolo, J-M. Lee, F. Karzai, V. Altamura, G. Scambia, G. Daniele
Journal: Annals of Oncology (2024)
1520P Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
Authors: A. Reichinger, H. Taghizadeh, T.K. Lentner, P. Reimann, T. Winder, D. Kiesl, F. Romeder, G. Webersinke, J. Burghofer, P. Kirchweger, J.M. Riedl, G. Prager, H. Rumpold, B. Doleschal
Journal: Annals of Oncology (2024)
1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Authors: K. Fizazi, G. Roubaud, A. Bernard-Tessier, G. Gravis, A. Flechon, R. Ratta, P. Barthelemy, R.J. Jones, O.A. Parikh, A. Hussain, J.C.M. van der Voet, N. Cook, M.M.E. Tanner, R.H. Jones, C. Garratt, T. Ikonen, P. Pohjanjousi, C.H. Poehlein, E.S. Antonarakis
Journal: Annals of Oncology (2024)
1522P S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Authors: Y. Tozuka, H. Imaoka, M. Ikeda, S. Kobayashi, A. Ohba, M. Ueno, Y. Suzuki, H. Tsumura, N. Kimura, S. Kawaguchi, Y. Kawamoto, S. Shimizu, M. Ueno, J. Furuse, H. Nagano
Journal: Annals of Oncology (2024)
1460P Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Authors: D. Kamp, A.M. May, M.J.M. van Velzen, R.H.A. Verhoeven, H.W.M. van Laarhoven, N. Haj Mohammad
Journal: Annals of Oncology (2024)
1580P Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Authors: C. Hage Chehade, A. Narang, Y. JUNG JO, Z.I. Ozay, G. Gebrael, N. Tripathi, B. Chigarira, A. Srivastava, R. Ji, D. Garg, V. Mathew Thomas, H. Li, S. Roy, B.L. Maughan, U. Swami, N. Agarwal
Journal: Annals of Oncology (2024)
1532TiP Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Authors: W. Park, E.M. O'Reilly, C-P. Li, D-Y. Oh, R. Garcia-Carbonero, G. Roth, T. Nakajima, D. Moran, J. Yang, R. Li, F. Kunieda
Journal: Annals of Oncology (2024)
1565P Improving lung cancer screening selection: Hunt Lung Cancer Model (HUNT LCM) versus PLCOm2012, early results after two rounds of screening in a prospective screening pilot study in Norway (TIDL)
Authors: O.D. Roe, I. Fotopoulos, O.T.D. Nguyen, I. Tsamardinos, V. Lagani, T.E. Strand, H. Ashraf
Journal: Annals of Oncology (2024)
1581P AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Authors: P.H. Thaker, W.M. Jose, S. Rath, P.S. Malik, P. Poddar, R. Mittal, B. Bhalgat, J. Ghosh, S. Nag
Journal: Annals of Oncology (2024)
1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Authors: A.A. Hamid, H. Thomas, A. Martin, Y.Y. Soon, L.G. Horvath, R. Zielinski, A. Thomson, H. Tan, S.K. Sandhu, M.N. Reaume, D.W. Pook, F. Parnis, R.S. McDermott, N. Lawrence, M. Frydenberg, K.N. Chi, M.R. Stockler, I.D. Davis, C. Sweeney
Journal: Annals of Oncology (2024)
1588P Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Authors: S. Di Bella, A.G. Agostara, M. Pelliccione, P. Candido, S. Della Torre, D. Toniolo, F. Zannier, A.P. Galeassi, V. Smiroldo, P. Belloni, C. Cozzi, D. Petruzzelli, R. Bollina
Journal: Annals of Oncology (2024)
1615P A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Authors: S. Halabi, B. Luo, S. Guo, L.H.M. Rydzewska, P.J. Godolphin, M.K. Parmar, M.A. Carducci, G. Gravis, N.D. James, J.F. Tierney, C. Sweeney
Journal: Annals of Oncology (2024)
1508P Tumor-specific circulating cell-free DNA (ctDNA) and its clinical value in predicting response to palliative systemic treatment or survival in patients with pancreatic cancer: A systematic review and meta-analysis
Authors: M.M. Steiniche, L.B. Callesen, E.H. Vlk, R.F. Andersen, T.F. Hansen, M. Ladekarl, K-L.G. Spindler
Journal: Annals of Oncology (2024)
1484P Inflammatory patterns of ascites in patients with solid tumors
Authors: M. Berger, M. Korpan, C. Peischl, K. Syböck, E. Tomasich, A. Kienzle, M. König, C. Englisch, M. Kleinberger, L. Gottmann, B. Fendl, L. Balcar, E.S. Bergen, T. Reiberger, B. Niederdorfer, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2024)
1462P A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Authors: B. Li, Q. Zheng, Z. Huang, Y. Sun, H. Hu, Y. Zhang, J. Xiang, Y. Li, H. Chen
Journal: Annals of Oncology (2024)
1530P Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2 positive locally advanced unresectable or metastaticpancreatic cancer
Authors: F. Liu, Y. Zhang, S. Zhang, J. Gong, M. Zhang, X. Liang, J. Wang, Y. Li, Z. Jin, Y. Yang, L. Shen
Journal: Annals of Oncology (2024)
1531TiP TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Authors: M.J. Overman, R. Laeufle, H. Singh, J. Henry, A.I. Spira, M. Chisamore, G. McGregor, H. Zou
Journal: Annals of Oncology (2024)
1592P Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Authors: B.C. Özdemir, A. Richters, S. Oertelt-Prigione, A.A. Adjei, S. Borchmann, J.B.A.G. Haanen, A. Letsch, A. Quaas, R.H.A. Verhoeven, A.D. Wagner
Journal: Annals of Oncology (2024)
1538O Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study
Authors: A.B. Cortot, M. Genin, F. Occelli, L. Dauchet, V. Leblanc, E. Auvray, M. Sabatini, F. Goupil, C. Dussopt, S. Thierry, P. Masson, M. Jaafar, C. Marthy, C. Maurer, S. Dehette, E. Wasielewski, A. Hamroun, D. Debieuvre, S. Leblanc
Journal: Annals of Oncology (2024)
1564P Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Authors: A. Ferrari, L. Van Bos, S. Talboom, W. van de Veerdonk, M. Pak, K. Depovere, M. Descan, S. Parmentier, L. Van Collie, M. Goossens, G. Van Hal
Journal: Annals of Oncology (2024)
1560P Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Authors: A. Ferrari, C. Cassani, F. Doyle, G. Rizzo, C.A.P. Anghelone, A. Della Valle, M. Rossi, A. Podesta, M. Campanella, A. Sgarella
Journal: Annals of Oncology (2024)
1526P Anti-PD-L1/TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine in previously untreated patients with locally advanced or metastatic pancreatic cancer: A multicenter, phase Ib/II study
Authors: J. Yuan, J. Zhou, L. Shen, X. Yu, R. Xue, M. Wei, Z. Li, Y. Zhou, Y. Wu, H. Han
Journal: Annals of Oncology (2024)
1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Authors: W.K. Kelly, L.J. Appleman, C-C. Lin, A.J. Armstrong, S.C. Fischer, D.W. Pook, J.L. Perez Gracia, J.L. Lee, D.R. Berthold, P.J. Ward, D.E. Castellano Gauna, L.G. Horvath, M. Kim, N. Matsubara, C. Sumey, M. Shabooti, Z. Yang, J. Connarn, J. Stieglmaier, D.C. Danila
Journal: Annals of Oncology (2024)
1523P Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Authors: Y. Sezgin, O. Karhan, Z. Urakci, N. Mecidova, M. Araz, A. Sakin, B.M. Ercek, M. Ürün, S. Urvay, M.B. Aykan, S. Kocak, M.O. Arici, N. Avci, A. Alkan, M. Ozcelik, M.N. Aldemir, Y. Ergün
Journal: Annals of Oncology (2024)
1533TiP A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Authors: X. Zhang, J. Cui, M. Quan, T. Zhang, D. Cao, Z. Li, D.T.C. Yang, X. Zhu, Y. Chen, P. Liang, L. Yao, L. Wang
Journal: Annals of Oncology (2024)
1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
Authors: K. Fizazi, M.J. Morris, N.D. Shore, K.N. Chi, M. Crosby, J.S. de Bono, K. Herrmann, G. Roubaud, J. Nagarajah, M.T. Fleming, B. Lewis, L.T. Nordquist, D.E. Castellano Gauna, N. Carnahan, S. Ghebremariam, M. Hertelendi, O. Sartor
Journal: Annals of Oncology (2024)
1558P Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Authors: E.T.T. Yacoub, M. Mohammed, A.H. Abdelaziz, E. Shash, H. ElGhazawy, N. Hussein, H.M. Amin, H.A. El Ghazaly, I. Shafik, K.S. Shohdy, L. Kassem
Journal: Annals of Oncology (2024)
1611P Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Authors: K.N. Chi, O. Sartor, K. Fizazi, J.S. de Bono, N.D. Shore, K. Herrmann, D.E. Castellano Gauna, J.M. Piulats Rodriguez, A. Flechon, X.X. Wei, H. Kim, M. Schweizer, S. Alanee, S. Ghebremariam, M. Hertelendi, M.J. Morris
Journal: Annals of Oncology (2024)
1556P Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Authors: J.C. Tapia, J. Gavira, D. Matthews, M. Santoni, M.N. Young, L. Blondel, R. Flippot, R. Frazer, G. Anguera, J.P. Maroto Rey
Journal: Annals of Oncology (2024)
1529P Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study
Authors: M. Wei, S. Shi, J. Li, N. Du, X. Yu, J. Xu
Journal: Annals of Oncology (2024)
1501P Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Authors: L. Tontini, A. Roncadori, R. Rossi, M. Pieri, I. Massa, W. Balzi, M.C. Pallotti, E. Parisi, D. Arpa, S. Micheletti, S. Cima, R.N. Abousiam, M.G. Muolo, G. Galeotti, S.P. Colangione, A.G. Morganti, M.C. Maltoni, A. Romeo
Journal: Annals of Oncology (2024)
1541MO Leadership roles in oncology: Gender is still a barrier. Results from the new ESMO Women for Oncology Committee authorship and monitoring studies
Authors: H. Linardou, J. Bajpai, U. Dafni, N.M.L. Battisti, R. Berardi, A. Bosch, F. Cardoso, C.M. De Cerqueira Mathias, S.P. Choo, E. Felip, K. Fizazi, E. Fountzilas, G. Dimopoulou, M.C. Garassino, D. Mukherji, J. Naidoo, J.W-H. Tsang, S. Peters, C. Sessa, P. Garrido Lopez
Journal: Annals of Oncology (2024)
1528P TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Authors: Y-Y. Su, L-Y. Bai, C-J. Huang, C-F. Chiu, H-T. Wang, J-S. Du, H-C. Wang, S. Chuang, Y-H. Shih, H-C. Lin, Y-S. Shan, L-T. Chen
Journal: Annals of Oncology (2024)
1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Authors: J.H. Strickler, J. Raimbourg, F. Ghiringhelli, J.E. Cohen, C. Kitagawa, M.R. Sharma, K.H. Lee, M. De Miguel, Z.N. Hunter, M. Burns, R.R. Li, N. Rudraganguly, C. Biesdorf de Almeida, K.J. Freise, M.E. Blaney, G. Morrison-Thiele, M.R. Neagu Aristide, Y. Kuboki
Journal: Annals of Oncology (2024)
1488P Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Authors: W.W.L. Chan, Y.L. Tai, H. Hou, E. Cheung, M. Liu, S. Siu, S.Y. Lam, J. Keung, K.K. Yuen
Journal: Annals of Oncology (2024)
1454P An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Authors: A. Kawazoe, S. Koyama, I. Nakayama, M. Wakabayashi, H. Furuya, K. Tsukamoto, H. Tamura, T. Ikeno, A. Sato, M. Kojima, T. Kuwata, T. Fujita, T. Kinoshita, H. Nishikawa, K. Shitara
Journal: Annals of Oncology (2024)
1521P Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
Authors: H. Imaoka, M. Ikeda, M. Ozaka, K. Oshima, N. Okano, S. Shimizu, H. Tsumura, Y. Komatsu, T. Yamashita, S. Kataoka, H. Nagano, T. Hisano, M. Sasaki, S. Kobayashi, T. Fukushima, S. Mitsunaga, T. Furukawa, S. Hamauchi, F. Hedouin-Biville, M. Ueno
Journal: Annals of Oncology (2024)
1516P Lung-only metastatic PDAC: Another disease?
Authors: L. Mercier, A. Boileve, M.P. Ducreux, A. Lambert, A. Tarabay, A. Hollebecque, C. Smolenschi, M. Delaye, M. Valery, T. Pudlarz, A.C. Fuerea, V. Boige
Journal: Annals of Oncology (2024)
1509P Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes
Authors: L. Gutierrez Sainz, V. Heredia, A.M. Rodríguez García, M.G. Crespo Sánchez, M.G. Serrano Olmedo, M. Molero Luis, M. Mendiola, J. Feliu
Journal: Annals of Oncology (2024)